Texas A&M and XOMA to Develop Next-Generation Biomanufacturing Systems

October 8, 2008

The Texas A&M University System (College Station, Texas) and XOMA, Ltd., (Berkeley, CA), have signed an agreement to explore options for developing and manufacturing antibodies and protein-based therapeutics for human and veterinary applications.

The Texas A&M University System (College Station, Texas) and XOMA, Ltd., (Berkeley, CA), have signed an agreement to explore options for developing and manufacturing antibodies and protein-based therapeutics for human and veterinary applications. The two organizations will work together to develop next-generation systems and processes to improve and accelerate protein and antibody manufacturing.

The organizations also plan to discuss the design and establishment of a state-of-the-art GMP manufacturing facility within the State of Texas to spur academic research in diverse biological and bioengineering disciplines, and create a world-class biological manufacturing capacity in Texas.

For Texas A&M, this program could result in a significant gain in expertise, capabilities, and capacity in monoclonal antibody research and production in the State of Texas. For XOMA, the program is intended to provide access to new processes and technologies, additional manufacturing capacity, process development facilities, and research personnel that could help accelerate the translation of XOMA's technologies into biomanufacturing.